Jarmil Peters, MD
Pulmonary Disease · Hot Springs, ARNPI 1952786634
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 114 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by GSK at 40.4% of the total. 2025 is the largest year on record at $906, 2.2 times the $413 reported in 2019. That places this record below the midpoint for pulmonary disease clinicians in AR, where the typical reported total is $3,332.
Across 114 payments — averaging $29.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Genentech USA, Inc.$430
- Inari Medical, Inc.$212
- Amgen$181
- AstraZeneca$162
- Mallinckrodt Hospital Products Inc.$111
- plus $880 from 18 others
What the payments were for
- Food & beverage$3,22397%
- Education$903%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 59 | $1,337 |
| Genentech USA, Inc. | 4 | $430 |
| Inari Medical, Inc. | 2 | $212 |
| Amgen | 4 | $181 |
| AstraZeneca | 4 | $162 |
| Mallinckrodt Hospital Products Inc. | 5 | $111 |
| Merck | 4 | $94 |
| Sanofi-aventis U.S. LLC | 1 | $90 |
| Sanofi | 3 | $82 |
| Boehringer Ingelheim | 4 | $81 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $79 |
| Regeneron Healthcare Solutions, Inc. | 3 | $64 |
| Mylan Specialty L.p. | 3 | $59 |
| Grifols USA, LLC | 2 | $52 |
| Medtronic | 1 | $51 |
| Verona Pharma, Inc. | 2 | $46 |
| Pulmonx Corporation | 2 | $42 |
| United Therapeutics Corporation | 1 | $27 |
| Actelion Pharmaceuticals US, Inc. | 1 | $26 |
| Insmed, Inc. | 1 | $25 |
| Philips North America LLC | 1 | $21 |
| Baxter Healthcare | 1 | $20 |
| Viatris Specialty LLC | 1 | $15 |
| Inogen, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XOLAIR$150
- Esbriet$125
- TEZSPIRE$121
- AREXVY$121
- AIRSUPRA$114
- FLOWTRIEVER CATHETER, S$113
- CT THROMBECTOMY SYSTEM KIT$113
- NUCALA$110
How this compares
$3,313 in reported general payments places this provider in the 45th percentile of 102 pulmonary disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ActharCorticotropin | 13 | $1,162,022 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 183 | $152,329 |
| Breo ElliptaFluticasone/Vilanterol | 73 | $40,412 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 65 | $37,039 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 31 | $31,075 |
| EliquisApixaban | 11 | $12,176 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 20 | $10,246 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $6,846 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 130 | $3,531 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 20 | $2,579 |
| Ventolin HfaAlbuterol Sulfate | 37 | $2,082 |
| Montelukast Sodium | 58 | $534 |
| Azithromycin | 29 | $407 |
| Roflumilast | 11 | $360 |
| Omeprazole | 19 | $316 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $111 | $1,162,02213 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,337 | $229,781321 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $162 | $37,92154 claims |
| Boehringer IngelheimStiolto Respimat | $81 | $10,24620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 102 pulmonary disease providers in Arkansas.
Other pulmonary disease in Hot Springs
- Jessica TreatHot Springs$13K
- Albert ChinnHot Springs$7K
- Anupama KaulHot Springs$5K
- Jovan GayleHot Springs$5K
- Ladly AbrahamConway$371K
- Daniel PaulRogers$244K
- Jason McKinneyRogers$86K
- Arturo MeadeFort Smith$67K
- Nikhil MeenaLittle Rock$63K
- Penchala MittadodlaRogers$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.